Scott Hutton is President, Chief Executive Officer, and Director of Biodesix (NASDAQ: BDSX) in Louisville, CO, where his personal leadership philosophy emphasizes helping people, giving back, and positively impacting/improving people’s health and lives. Under his leadership, Biodesix has grown into a leading diagnostics company with a great company culture most recently recognized by Inc. Magazine as a Best Workplace for 2024. In 2020, during the global pandemic, Hutton led the Biodesix team through an October initial public offering (IPO).Hutton is an accomplished, inspirational, and strategic leader with 25+ years of experience in the diagnostic and medical device industries. He has a proven track record of successfully recruiting, developing, and leading high performance teams credited with 50+ product launches positively impacting tens of millions of patients globally. He joined Biodesix from Spectranetics (NASDAQ: SPNC), now part of Royal Philips (NYSE: PHG), where he served, until acquisition, as Senior Vice President and General Manager of the Vascular Intervention division. Prior to joining Spectranetics, Hutton spent 16+ years at Medtronic (NYSE: MDT) where he most recently led the Neurosurgery business unit as Vice President and General Manager. Hutton is a Purdue University grad, having earned a Bachelor of Arts degree from the College of Health and Human Sciences, Department of Health and Kinesiology, in 1995. Hutton was an active member of Delta Delta Chapter of Sigma Chi Fraternity. Hutton currently serves on the Coalition for 21st Century Medicine (C21) Board of Directors and Eximis Surgical Board of Directors. He has held many advisory, director and observer positions, including Colorado BioScience Association (CBSA) Board of Directors, Aqueduct Critical Care Board of Directors Observer, and Visualase Board of Directors Observer.Hutton’s achievements/recognition include being named a Top 25 Biotech Executive of 2024 by the Healthcare Technology Report, receiving the 2022 Purdue University Health and Kinesiology Distinctive Service Award, receiving the 2022 Purdue University Health and Human Sciences Distinguished Alumni Award, being named a Top 25 Biotech CEO of 2022 by the Healthcare Technology Report, being named a 2021 Purdue University Old Master, receiving the 2021 Significant Sig Award from Sigma Chi Fraternity, being named a Top 25 Biotech CEO of 2021 by the Healthcare Technology Report, being named 2020 CEO of the Year-USA by CEO Monthly Magazine, and receiving the 2011 Medtronic Wallin Leadership Award.
Listed skills include Medical Devices, Leadership, Product Launch, Cross Functional Team Leadership, and 43 others.